CTT PHARMACEUTICAL HOLDINGS, INC.
CTTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CTTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTTH
CTT Pharmaceutical Holdings, Inc. is a development-stage company focused on an oral delivery system for medications using a dispersible film (Wafer), with no revenues and a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2015.
Tracking 8 clinical trials · 4 catalysts for CTT PHARMACEUTICAL HOLDINGS, INC..
CTT Pharmaceutical Holdings, Inc. is a development-stage company focused on an oral delivery system for medications using a dispersible film (Wafer), with no revenues and a going concern uncertainty.
- CTT Pharma is a development-stage company focused on an oral delivery system for medications on dispersible film [sec · filed 2014-09-11].
- As of September 30, 2015, the company had cash of $32,121 and total assets of $922,038 [sec_mda · as of 2015-11-23].
- The company reported an accumulated deficit of $208,569 as of May 31, 2014 [sec · filed 2014-09-11].
- The company has not generated any revenues and may never attain profitability [sec · filed 2014-09-11].
- The company's continuation as a going concern is dependent on raising additional capital, which is uncertain [sec_mda · as of 2015-11-23].
What works
- The company is developing a novel oral delivery system (Wafer) that could differentiate it in the pharmaceutical market [sec · filed 2014-09-11].
- The company has a focused strategy on reducing non-strategic spending and pursuing strategic development initiatives [sec · filed 2014-09-11].
What to weigh
- The company has a limited operating history and has not generated any revenues, with no expectation of significant revenues in the short term [sec · filed 2014-09-11].
- The company faces significant competition from larger pharmaceutical and biotechnology firms with greater resources [sec · filed 2014-09-11].
- The company has an accumulated deficit and requires substantial additional capital to continue operations, with no guarantee of funding [sec · filed 2014-09-11].
- There is no guarantee that any product candidates will perform as hoped or be successfully commercialized [sec · filed 2014-09-11].
From the filings
Quoted directly from source documents.
The company is a development-stage entity with no revenues.
“As of the date of this report, we have not generated any r”
SEC filings · September 11, 2014
The company has a going concern uncertainty.
“Our continuation as a going concern is dependent upon, amongst other things, continued financial support from our shareholders, attaining a satisfactory revenue level, attainment of profitable operations and the generation of cash from operations and the ability to secure new financing arrangements and new capital to carry out our business plan.”
SEC MD&A · November 23, 2015
The company's cash position as of September 30, 2015.
“At September 30, 2015 and December 31, 2014. Current assets at September 30, 2015 were $922,038 as compared to $1,049,734 at December 31, 2014, a decline of approximately 12%. The primary reason for this decline is attributable to a decline in cash from $81,179 to $32,121”
SEC MD&A · November 23, 2015
The company faces intense competition.
“Many of our competitors have and employ greater financial and other resources, including larger research and development, marketing and manufacturing organizations.”
SEC filings · September 11, 2014
Catalyst timeline
- 2026-12-30 · Phase3_Topline — Topline results from a Phase II/III trial on efficacy of a product candidate; outcome could affect the company's prospects.
- 2027-12-31 · Phase3_Topline · arn-509 — Topline results from a Phase III study of ARN-509 in men; may influence the company's pipeline value.
- 2027-12-31 · Phase3_Topline · apalutamide — Topline results from a Phase III study of apalutamide plus androgen deprivation therapy; potential catalyst for the company.
- 2027-12-31 · Phase3_Topline · jnj-56021927 — Topline results from a Phase III study of JNJ-56021927 in combination with abiraterone; could impact the company's outlook.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's ability to continue as a going concern depends on raising additional capital, which is not assured [sec_mda · as of 2015-11-23].
- No revenue generation — The company has not generated any revenues and may never achieve profitability [sec · filed 2014-09-11].
- Competitive pressure — Larger competitors with greater resources may render the company's technology obsolete [sec · filed 2014-09-11].
- Commercialization risk — There is no guarantee that the Wafer or any product candidate will be successfully commercialized [sec · filed 2014-09-11].
What to watch
- Ability to secure additional financing to fund operations and product development [sec · filed 2014-09-11].
- Progress in the development and potential commercialization of the Wafer oral delivery system [sec · filed 2014-09-11].
- Any changes in cash position or accumulated deficit in future filings [sec_mda · as of 2015-11-23].
- Regulatory or competitive developments that could impact the company's technology [sec · filed 2014-09-11].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run CTT PHARMACEUTICAL HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CTT PHARMACEUTICAL HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
57.8 months
D/E 0.25
No tracked pipeline phase
No tracked pipeline candidates
4 upcoming, next in ~122d
5 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for CTT PHARMACEUTICAL HOLDINGS, INC.?
CTT Pharmaceutical Holdings, Inc. is a development-stage company focused on an oral delivery system for medications using a dispersible film (Wafer), with no revenues and a going concern uncertainty.
What is CTT PHARMACEUTICAL HOLDINGS, INC.'s next catalyst?
CTT PHARMACEUTICAL HOLDINGS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic" — expected December 30, 2026.
Who is the CEO of CTT PHARMACEUTICAL HOLDINGS, INC.?
Mr. Ryan Khouri is the chief executive officer of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH).
Where is CTT PHARMACEUTICAL HOLDINGS, INC. headquartered?
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) is headquartered in Tampa, FL, United States.
What therapeutic areas does CTT PHARMACEUTICAL HOLDINGS, INC. focus on?
CTT PHARMACEUTICAL HOLDINGS, INC. develops therapies across Oncology, Infectious Disease, Respiratory, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.